{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:06:30Z","timestamp":1786975590320,"version":"build-2736575974"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:sec id=\"ab-dbr220022-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>\n                      A new treatment for cystic fibrosis combining 3\n                      <jats:italic>CFTR<\/jats:italic>\n                      modulators\u2014elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA)\u2014has recently been approved for cystic fibrosis treatment. The cutaneous adverse effects following treatment with this combination are poorly described in the literature.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr220022-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the clinicopathological features and treatment response of ELX-TEZ-IVA\u2013associated acneiform eruptions in patients with cystic fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr220022-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This case series study was conducted in the Dermatology Department of Cochin Hospital, Paris, France, from July 2021 to June 2022 in collaboration with the Cochin Reference Center for Cystic Fibrosis. Referred patients were examined by senior dermatologists. All patients with cystic fibrosis treated with ELX-TEZ-IVA and referred for an acneiform rash were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr220022-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Treatment with ELX-TEZ-IVA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr220022-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Onset of acneiform rash, type of lesions, and degree of severity, as well as treatments initiated and response, were evaluated. When performed, skin biopsies were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr220022-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 16 patients (11 women [68.7%]) with a median (range) age of 27 (22-38) years. Six patients (37.5%) developed new-onset acneiform rashes, whereas 10 patients (62.5%) had a relapse (5 patients) or worsening (5 patients) of previous acne. The median (range) onset of acneiform rash was 45 (15-150) days. At inclusion, 11 patients (68.7%) had facial hyperseborrhea, 15 patients (93.7%) had noninflammatory lesions, and 14 (87.5%) had inflammatory lesions of seborrheic regions. Four patients (25.0%) had severe acne with deep inflammatory lesions and pitted scars. A specific pathological pattern of necrotizing infundibular crystalline folliculitis was observed in 4 patients. Topical acne treatments, antibiotics, and isotretinoin were used successfully in these patients, resulting in partial or complete remission in 12 patients (85.7% of patients reevaluated).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr220022-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This case series study found that acneiform eruption is an adverse event associated with ELX-TEZ-IVA treatment in patients with cystic fibrosis. Most patients developed mild lesions. However, isotretinoin treatment may be necessary in some patients. The mechanism of ELX-TEZ-IVA\u2013associated acneiform eruption is currently unknown, but the observation of necrotizing infundibular crystalline folliculitis in biopsied patients may guide further exploration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2022.5208","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T11:33:24Z","timestamp":1669808004000},"page":"68","source":"Crossref","is-referenced-by-count":18,"title":["Acneiform Eruption Following Elexacaftor-Tezacaftor-Ivacaftor Treatment in Patients With Cystic Fibrosis"],"prefix":"10.1001","volume":"159","author":[{"given":"L\u00e9a","family":"Okroglic","sequence":"first","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Cochin, AP-HP, AP-HP.Centre-Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sohier","sequence":"additional","affiliation":[{"name":"Department of Pathology, H\u00f4pital Cochin, AP-HP, AP-HP.Centre-Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Facult\u00e9 de M\u00e9decine Paris Centre Sant\u00e9, University Paris Cit\u00e9, Paris, France"},{"name":"Institut Cochin, INSERM U1016, UMR 8104, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Martin","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de M\u00e9decine Paris Centre Sant\u00e9, University Paris Cit\u00e9, Paris, France"},{"name":"Institut Cochin, INSERM U1016, UMR 8104, Paris, France"},{"name":"Department of Respiratory Medicine and National Cystic Fibrosis Reference Center, H\u00f4pital Cochin, AP-HP, AP-HP.Centre-Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Lheure","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Cochin, AP-HP, AP-HP.Centre-Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Institut Cochin, INSERM U1016, UMR 8104, Paris, France"},{"name":"Study Group on Facial Dermatoses of the French Society of Dermatology (DEFI), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Franck","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Cochin, AP-HP, AP-HP.Centre-Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Honor\u00e9","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and National Cystic Fibrosis Reference Center, H\u00f4pital Cochin, AP-HP, AP-HP.Centre-Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Kanaan","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and National Cystic Fibrosis Reference Center, H\u00f4pital Cochin, AP-HP, AP-HP.Centre-Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de M\u00e9decine Paris Centre Sant\u00e9, University Paris Cit\u00e9, Paris, France"},{"name":"Institut Cochin, INSERM U1016, UMR 8104, Paris, France"},{"name":"Department of Respiratory Medicine and National Cystic Fibrosis Reference Center, H\u00f4pital Cochin, AP-HP, AP-HP.Centre-Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Carlotti","sequence":"additional","affiliation":[{"name":"Department of Pathology, H\u00f4pital Cochin, AP-HP, AP-HP.Centre-Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Dupin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Cochin, AP-HP, AP-HP.Centre-Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Facult\u00e9 de M\u00e9decine Paris Centre Sant\u00e9, University Paris Cit\u00e9, Paris, France"},{"name":"Institut Cochin, INSERM U1016, UMR 8104, Paris, France"},{"name":"Study Group on Facial Dermatoses of the French Society of Dermatology (DEFI), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Oul\u00e8s","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Cochin, AP-HP, AP-HP.Centre-Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Facult\u00e9 de M\u00e9decine Paris Centre Sant\u00e9, University Paris Cit\u00e9, Paris, France"},{"name":"Institut Cochin, INSERM U1016, UMR 8104, Paris, France"},{"name":"Study Group on Facial Dermatoses of the French Society of Dermatology (DEFI), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"dbr220022r1","doi-asserted-by":"publisher","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis.","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"19","key":"dbr220022r2","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele.","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"dbr220022r3","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-201554","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development.","volume":"2013","author":"Gagnier","year":"2013","journal-title":"BMJ Case Rep"},{"issue":"1","key":"dbr220022r4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/jdv.2010.25.issue-1","article-title":"Development and evaluation of a Global Acne Severity Scale (GEA Scale) suitable for France and Europe.","volume":"25","author":"Dr\u00e9no","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"dbr220022r5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions.","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"dbr220022r6","doi-asserted-by":"publisher","DOI":"10.5070\/D3271156096","article-title":"An acneiform eruption associated with elexacaftor\/tezacaftor\/ivacaftor treatment.","volume":"27","author":"Breneman","year":"2021","journal-title":"Dermatol Online J"},{"issue":"4","key":"dbr220022r7","doi-asserted-by":"publisher","DOI":"10.46998\/IJCMCR","article-title":"Severe abdominal pain and acne vulgaris after the initiation of elexacaftor\/tezacaftor\/ivacaftor (ELX\/TEZ\/IVA).","volume":"12","author":"Nasr","year":"2021","journal-title":"Int J Clin Stud Med Case Rep"},{"issue":"2","key":"dbr220022r8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1046\/j.1365-2133.1999.02983.x","article-title":"Transepidermal elimination of urate-like crystals: a new perforating disorder?","volume":"141","author":"Lucke","year":"1999","journal-title":"Br J Dermatol"},{"issue":"2","key":"dbr220022r9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.clindermatol.2020.10.013","article-title":"Necrotizing infundibular (ostial) crystalline folliculitis.","volume":"39","author":"Roux","year":"2021","journal-title":"Clin Dermatol"},{"issue":"1","key":"dbr220022r10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1046\/j.1365-2133.2001.04305.x","article-title":"Necrotizing infundibular crystalline folliculitis.","volume":"145","author":"Kossard","year":"2001","journal-title":"Br J Dermatol"},{"issue":"6","key":"dbr220022r11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/00015550410018370","article-title":"Demonstration of polarizable crystals in fresh comedonal extracts: sebum crystallizes.","volume":"84","author":"Gonz\u00e1lez-Serva","year":"2004","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"dbr220022r12","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/DAD.0000000000002022","article-title":"Eruptive necrotizing infundibular crystalline folliculitis: an expression of an abortive sebaceous follicular repair pathway linked to committed infundibular stem cells?","volume":"43","author":"Kossard","year":"2021","journal-title":"Am J Dermatopathol"},{"issue":"10","key":"dbr220022r13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/DAD.0000000000000743","article-title":"Necrotizing infundibular crystalline folliculitis (NICF) induced by anti-tumoral therapies: report of 2 cases.","volume":"39","author":"Fattouh","year":"2017","journal-title":"Am J Dermatopathol"},{"issue":"6","key":"dbr220022r14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/cup.v47.6","article-title":"Dermatomal necrotizing infundibular crystalline folliculitis following herpes zoster in a patient on PD-1 inhibitor therapy.","volume":"47","author":"Fischer","year":"2020","journal-title":"J Cutan Pathol"},{"issue":"6","key":"dbr220022r15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00418-016-1535-3","article-title":"Expression of epithelial sodium channel (ENaC) and CFTR in the human epidermis and epidermal appendages.","volume":"147","author":"Hanukoglu","year":"2017","journal-title":"Histochem Cell Biol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2798845\/jamadermatology_okroglic_2022_br_220022_1673370630.90813.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T11:02:44Z","timestamp":1674039764000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2798845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.5208","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,1]]}}}